Induction of antitumor immune response by homeostatic proliferation and CD28 signaling

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 4596-4605

  Suzuki, Toshihiro ^a   Ogawa, Shuhei ^a   Tanabe, Kazunari ^b   Tahara, Hideaki ^c   Abe, Ryo ^a   Kishimoto, Hidehiro ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 2; L SELECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; DRUG SCREENING; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD44; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; HOMEOSTASIS; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; L-SELECTIN; MICE; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44449155427     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.4596     Document Type: Article

References (48)

1. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3: 999-1005.
2. + T cells. J. Exp. Med. 198: 569-580.
3. Rosenberg, S. A., and M. E. Dudley. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2): 14639-14645.
4. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909 -915.
5. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopu- lation with antitumor lymphocytes. Science 298: 850 -854.
6. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93: 7855-7860.
7. Rosenberg, S. A. 1988. Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans. J. Clin. Oncol. 6: 403-406.
8. Dudley, M. E., J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24: 363-373.
9. Surh, C. D., and J. Sprent. 2005. Regulation of mature T cell homeostasis. Semin. Immunol. 17: 183-191.
10. Dummer, W., A. G. Niethammer, R. Baccala, B. R. Lawson, N. Wagner, R. A. Reisfeld, and A. N. Theofilopoulos. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110: 185-192.
11. Wang, L. X., R. Li, G. Yang, M. Lim, A. O'Hara, Y. Chu, B. A. Fox, N. P. Restifo, W. J. Urba, and H. M. Hu. 2005. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65: 10569 -10577.
12. + cells. J. Exp. Med. 195: 1523-1532.
13. + memory T cells by opposing cytokines. Science 288: 675-678.
14. Tan, J. T., E. Dudl, E. LeRoy, R. Murray, J. Sprent, K. I. Weinberg, and C. D. Surh. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 98: 8732-8737.
15. Seddon, B., P. Tomlinson, and R. Zamoyska. 2003. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 4: 680-686.
16. Cho, B. K., V. P. Rao, Q. Ge, H. N. Eisen, and J. Chen. 2000. Homeostasis stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192: 549 -565.
17. Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192: 557-564.
18. Murali-Krishna, K., and R. Ahmed. 2000. Cutting edge: Naive T cells masquerading as memory cells. J. Immunol. 165: 1733-1737.
19. + T cells: costimulatory requirements and role in memory formation. J. Immunol. 167: 3699 -3707.
20. Prlic, M., B. R. Blazar, A. Khoruts, T. Zell, and S. C. Jameson. 2001. Homeostatic expansion occurs independently of costimulatory signals. J. Immunol. 167: 5664-5668.
21. Hagen, K. A., C. T. Moses, E. F. Drasler, K. M. Podetz-Pedersen, S. C. Jameson, and A. Khoruts. 2004. A role for CD28 in lymphopenia-induced proliferation of CD4 T cells. J. Immunol. 173: 3909 -3915.
22. Hellstrom, K. E., I. Hellstrom, and L. Chen. 1995. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145: 123-145.
23. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14: 483-486.
24. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11: 286 -293.
25. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
26. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261: 609 -612.
27. Shu, S. Y., T. Chou, and K. Sakai. 1989. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 143: 740 -748.
28. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161: 2187-2194.
29. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoan- tibody production in murine lupus on CD86 costimulatory molecule. Eur. J. Immunol. 25: 3060 -3069.
30. Hathcock, K. S., G. Laszlo, H. B. Dickler, J. Bradshaw, P. Linsley, and R. J. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262: 905-907.
31. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
32. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
33. Bracci, L., F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, and E. Proietti. 2007. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13: 644-653.
34. Rosenberg, S. A., J. J. Mule, P. J. Spiess, C. M. Reichert, and S. L. Schwarz. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161: 1169 -1188.
35. + T cell anergy and promotes tumor rejection. J. Immunol. 177: 4521-4529.
36. Bradley, L. M., L. Haynes, and S. L. Swain. 2005. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 26: 172-176.
37. Li, J., G. Huston, and S. L. Swain. 2003. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. 198: 1807-1815.
38. Yu, X., R. Abe, and R. J. Hodes. 1998. The role of B7-CD28 co-stimulation in tumor rejection. Int. Immunol. 10: 791-797.
39. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179: 523-532.
40. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90: 6586-6590.
41. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11: 191-212.
42. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155: 1063-1074.
43. + T cells. Nat. Immunol 7: 475-481.
44. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177: 1791-1796.
45. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763.
46. Min, B., H. Yamane, J. Hu-Li, and W. E. Paul. 2005. Spontaneous and homeo- static proliferation of CD4 T cells are regulated by different mechanisms. J. Immunol. 174: 6039 -6044.
47. + T cells. Proc. Natl. Acad. Sci. USA 101: 1969 -1974.
48. Alpdogan, O., and M. R. van den Brink. 2005. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 26: 56-64.